J 2024

European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE et. al.

Základní údaje

Originální název

European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

Autoři

KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ (203 Česká republika, domácí), Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN a Richard VAN HILLEGERSBERG

Vydání

European Journal of Cancer, London, ELSEVIER, 2024, 0959-8049

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 8.400 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001284009600001

Klíčová slova anglicky

Esophageal cancer; Gastric cancer; Metastasis; Metastasectomy; Stereotactic body radiotherapy; Oligometastasis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 15. 8. 2024 12:02, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. Results: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with <= 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. F-18-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI <= 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. Discussion: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.